| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shoulder Joint | 110 | 2024 | 643 | 19.450 |
Why?
|
| Rotator Cuff Injuries | 61 | 2024 | 314 | 15.120 |
Why?
|
| Arthroscopy | 111 | 2023 | 974 | 14.760 |
Why?
|
| Rotator Cuff | 56 | 2024 | 297 | 10.900 |
Why?
|
| Joint Instability | 49 | 2023 | 392 | 10.750 |
Why?
|
| Tenodesis | 40 | 2023 | 175 | 10.340 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 38 | 2022 | 211 | 8.510 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 32 | 2022 | 213 | 7.510 |
Why?
|
| Baseball | 22 | 2023 | 101 | 7.070 |
Why?
|
| Humans | 376 | 2024 | 26246 | 6.710 |
Why?
|
| Shoulder | 38 | 2024 | 191 | 6.300 |
Why?
|
| Tendon Injuries | 29 | 2022 | 206 | 6.260 |
Why?
|
| Anterior Cruciate Ligament Injuries | 29 | 2023 | 202 | 6.050 |
Why?
|
| Shoulder Injuries | 26 | 2022 | 148 | 5.850 |
Why?
|
| Anterior Cruciate Ligament | 35 | 2022 | 182 | 5.840 |
Why?
|
| Orthopedic Procedures | 29 | 2023 | 309 | 5.420 |
Why?
|
| Shoulder Dislocation | 19 | 2022 | 113 | 5.340 |
Why?
|
| Range of Motion, Articular | 78 | 2024 | 694 | 5.120 |
Why?
|
| Knee Joint | 53 | 2023 | 759 | 5.030 |
Why?
|
| Patient Reported Outcome Measures | 40 | 2024 | 495 | 5.010 |
Why?
|
| Treatment Outcome | 112 | 2024 | 3381 | 4.710 |
Why?
|
| Adult | 150 | 2023 | 7441 | 4.690 |
Why?
|
| Middle Aged | 149 | 2022 | 8589 | 4.560 |
Why?
|
| Muscle, Skeletal | 31 | 2022 | 363 | 4.560 |
Why?
|
| Athletic Injuries | 19 | 2022 | 167 | 4.350 |
Why?
|
| Suture Anchors | 14 | 2023 | 92 | 4.000 |
Why?
|
| Male | 182 | 2022 | 14117 | 3.900 |
Why?
|
| Tendons | 26 | 2023 | 218 | 3.870 |
Why?
|
| Retrospective Studies | 86 | 2023 | 3365 | 3.760 |
Why?
|
| Knee Injuries | 25 | 2023 | 208 | 3.530 |
Why?
|
| Return to Sport | 17 | 2023 | 155 | 3.490 |
Why?
|
| Female | 164 | 2023 | 14509 | 3.450 |
Why?
|
| Postoperative Complications | 31 | 2022 | 866 | 3.160 |
Why?
|
| Cadaver | 44 | 2023 | 369 | 3.080 |
Why?
|
| Elbow Joint | 15 | 2023 | 125 | 3.000 |
Why?
|
| Tibia | 17 | 2020 | 256 | 2.970 |
Why?
|
| Femur | 15 | 2020 | 383 | 2.920 |
Why?
|
| Biomechanical Phenomena | 51 | 2023 | 640 | 2.880 |
Why?
|
| Young Adult | 58 | 2023 | 1888 | 2.870 |
Why?
|
| Collateral Ligament, Ulnar | 9 | 2023 | 26 | 2.810 |
Why?
|
| Upper Extremity | 13 | 2022 | 63 | 2.800 |
Why?
|
| Glenoid Cavity | 8 | 2022 | 39 | 2.760 |
Why?
|
| Bone Screws | 14 | 2023 | 149 | 2.590 |
Why?
|
| Minimal Clinically Important Difference | 16 | 2022 | 163 | 2.580 |
Why?
|
| Cartilage, Articular | 14 | 2023 | 413 | 2.550 |
Why?
|
| Adolescent | 56 | 2023 | 2080 | 2.480 |
Why?
|
| Tendinopathy | 9 | 2022 | 53 | 2.410 |
Why?
|
| Aged | 79 | 2021 | 8754 | 2.380 |
Why?
|
| Orthopedics | 7 | 2020 | 116 | 2.340 |
Why?
|
| Sports Medicine | 7 | 2022 | 38 | 2.330 |
Why?
|
| Scapula | 15 | 2021 | 90 | 2.250 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2023 | 1146 | 2.150 |
Why?
|
| Bone Transplantation | 15 | 2023 | 220 | 2.140 |
Why?
|
| Arthroplasty | 14 | 2020 | 146 | 2.110 |
Why?
|
| Osteoarthritis | 13 | 2020 | 316 | 2.050 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2020 | 716 | 2.030 |
Why?
|
| Tibial Meniscus Injuries | 6 | 2022 | 87 | 1.880 |
Why?
|
| Athletes | 10 | 2023 | 80 | 1.870 |
Why?
|
| Bankart Lesions | 4 | 2023 | 14 | 1.870 |
Why?
|
| Suture Techniques | 15 | 2023 | 150 | 1.850 |
Why?
|
| Pain | 20 | 2023 | 389 | 1.840 |
Why?
|
| Ulnar Collateral Ligament Reconstruction | 5 | 2023 | 17 | 1.820 |
Why?
|
| Recovery of Function | 20 | 2019 | 283 | 1.750 |
Why?
|
| Surgeons | 4 | 2023 | 79 | 1.670 |
Why?
|
| Arm | 15 | 2022 | 81 | 1.620 |
Why?
|
| Internship and Residency | 3 | 2020 | 207 | 1.560 |
Why?
|
| Patient Readmission | 10 | 2021 | 129 | 1.520 |
Why?
|
| Humerus | 11 | 2021 | 112 | 1.490 |
Why?
|
| Reoperation | 22 | 2021 | 883 | 1.460 |
Why?
|
| Allografts | 14 | 2023 | 229 | 1.450 |
Why?
|
| Shoulder Pain | 8 | 2020 | 56 | 1.390 |
Why?
|
| Workers' Compensation | 9 | 2021 | 71 | 1.390 |
Why?
|
| Biological Products | 2 | 2023 | 44 | 1.380 |
Why?
|
| Recurrence | 18 | 2021 | 314 | 1.370 |
Why?
|
| Collateral Ligaments | 4 | 2023 | 25 | 1.370 |
Why?
|
| Menisci, Tibial | 11 | 2022 | 177 | 1.310 |
Why?
|
| Surveys and Questionnaires | 16 | 2020 | 1075 | 1.280 |
Why?
|
| Ligaments, Articular | 12 | 2023 | 106 | 1.280 |
Why?
|
| Acromion | 5 | 2020 | 26 | 1.280 |
Why?
|
| Bone Diseases | 2 | 2019 | 24 | 1.250 |
Why?
|
| Elbow | 9 | 2023 | 52 | 1.230 |
Why?
|
| Computer Simulation | 6 | 2022 | 193 | 1.200 |
Why?
|
| Follow-Up Studies | 31 | 2021 | 1735 | 1.200 |
Why?
|
| Wound Healing | 11 | 2017 | 149 | 1.180 |
Why?
|
| Return to Work | 6 | 2021 | 64 | 1.170 |
Why?
|
| Arthroplasty, Subchondral | 4 | 2015 | 30 | 1.170 |
Why?
|
| Shoulder Fractures | 4 | 2021 | 31 | 1.160 |
Why?
|
| United States | 23 | 2021 | 1991 | 1.110 |
Why?
|
| Transplantation, Homologous | 17 | 2022 | 287 | 1.100 |
Why?
|
| Osteoarthritis, Knee | 9 | 2023 | 361 | 1.100 |
Why?
|
| Prospective Studies | 19 | 2023 | 1673 | 1.090 |
Why?
|
| Clinical Competence | 3 | 2018 | 211 | 1.040 |
Why?
|
| Aged, 80 and over | 29 | 2020 | 4675 | 1.040 |
Why?
|
| Bone Resorption | 4 | 2019 | 83 | 1.020 |
Why?
|
| Imaging, Three-Dimensional | 15 | 2021 | 217 | 1.010 |
Why?
|
| Bone-Patellar Tendon-Bone Grafting | 6 | 2020 | 34 | 0.990 |
Why?
|
| Fractures, Stress | 2 | 2023 | 21 | 0.990 |
Why?
|
| Fracture Fixation, Internal | 5 | 2021 | 64 | 0.980 |
Why?
|
| Acromioclavicular Joint | 2 | 2018 | 16 | 0.980 |
Why?
|
| Patellar Ligament | 5 | 2015 | 42 | 0.970 |
Why?
|
| Cohort Studies | 17 | 2023 | 1842 | 0.960 |
Why?
|
| Arthroplasty, Replacement | 7 | 2016 | 146 | 0.950 |
Why?
|
| Clavicle | 3 | 2018 | 14 | 0.940 |
Why?
|
| Social Media | 2 | 2022 | 39 | 0.940 |
Why?
|
| Platelet-Rich Plasma | 5 | 2021 | 89 | 0.930 |
Why?
|
| Sports | 2 | 2022 | 54 | 0.930 |
Why?
|
| Exercise Therapy | 4 | 2020 | 95 | 0.920 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2021 | 102 | 0.920 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 104 | 0.910 |
Why?
|
| Time Factors | 17 | 2020 | 1382 | 0.890 |
Why?
|
| Quality Improvement | 3 | 2020 | 151 | 0.890 |
Why?
|
| Operative Time | 4 | 2020 | 84 | 0.880 |
Why?
|
| Basketball | 2 | 2023 | 14 | 0.880 |
Why?
|
| Rotation | 17 | 2021 | 129 | 0.880 |
Why?
|
| Stress, Mechanical | 7 | 2020 | 160 | 0.880 |
Why?
|
| Postoperative Period | 17 | 2022 | 312 | 0.860 |
Why?
|
| Length of Stay | 7 | 2022 | 304 | 0.850 |
Why?
|
| Risk Factors | 22 | 2022 | 2271 | 0.850 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 44 | 0.830 |
Why?
|
| Journal Impact Factor | 1 | 2022 | 19 | 0.830 |
Why?
|
| Workload | 2 | 2022 | 29 | 0.810 |
Why?
|
| Meniscectomy | 2 | 2019 | 27 | 0.800 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2022 | 5 | 0.800 |
Why?
|
| Open Fracture Reduction | 1 | 2021 | 5 | 0.780 |
Why?
|
| Tympanoplasty | 1 | 2021 | 3 | 0.780 |
Why?
|
| Tympanic Membrane Perforation | 1 | 2021 | 3 | 0.780 |
Why?
|
| Otitis Media | 1 | 2021 | 4 | 0.780 |
Why?
|
| Anesthesia | 1 | 2022 | 31 | 0.770 |
Why?
|
| Wounds and Injuries | 3 | 2019 | 31 | 0.770 |
Why?
|
| Quality of Life | 10 | 2022 | 620 | 0.770 |
Why?
|
| Pain, Postoperative | 10 | 2022 | 309 | 0.770 |
Why?
|
| Depression | 4 | 2021 | 409 | 0.770 |
Why?
|
| Joint Capsule | 4 | 2016 | 46 | 0.760 |
Why?
|
| Football | 4 | 2019 | 34 | 0.750 |
Why?
|
| Rupture | 14 | 2021 | 107 | 0.750 |
Why?
|
| Fractures, Bone | 3 | 2023 | 76 | 0.730 |
Why?
|
| Amputees | 1 | 2020 | 1 | 0.710 |
Why?
|
| Artificial Limbs | 1 | 2020 | 6 | 0.710 |
Why?
|
| Activities of Daily Living | 11 | 2022 | 561 | 0.710 |
Why?
|
| Muscle Strength | 8 | 2020 | 133 | 0.710 |
Why?
|
| Age Factors | 13 | 2020 | 750 | 0.700 |
Why?
|
| Analgesics, Opioid | 7 | 2022 | 210 | 0.690 |
Why?
|
| Patient Satisfaction | 9 | 2021 | 311 | 0.670 |
Why?
|
| Weight Lifting | 1 | 2019 | 9 | 0.660 |
Why?
|
| Demography | 1 | 2019 | 71 | 0.660 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2022 | 100 | 0.650 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2019 | 72 | 0.650 |
Why?
|
| Tendon Transfer | 3 | 2014 | 20 | 0.650 |
Why?
|
| Sutures | 6 | 2023 | 45 | 0.640 |
Why?
|
| Joint Dislocations | 2 | 2019 | 56 | 0.630 |
Why?
|
| Tissue Transplantation | 2 | 2016 | 18 | 0.630 |
Why?
|
| Bone Marrow Transplantation | 1 | 2018 | 23 | 0.630 |
Why?
|
| Electromyography | 7 | 2021 | 59 | 0.630 |
Why?
|
| Cost-Benefit Analysis | 5 | 2022 | 126 | 0.620 |
Why?
|
| Disability Evaluation | 4 | 2020 | 290 | 0.620 |
Why?
|
| Movement | 3 | 2016 | 108 | 0.610 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 81 | 0.610 |
Why?
|
| Materials Testing | 3 | 2017 | 132 | 0.610 |
Why?
|
| Databases, Factual | 11 | 2019 | 332 | 0.580 |
Why?
|
| Health Care Costs | 1 | 2018 | 72 | 0.580 |
Why?
|
| ROC Curve | 6 | 2020 | 137 | 0.570 |
Why?
|
| Leishmaniasis, Visceral | 8 | 2015 | 8 | 0.570 |
Why?
|
| Simulation Training | 1 | 2018 | 38 | 0.570 |
Why?
|
| Hospitalization | 2 | 2018 | 295 | 0.570 |
Why?
|
| Pain Measurement | 14 | 2020 | 454 | 0.570 |
Why?
|
| Osteochondritis Dissecans | 2 | 2015 | 25 | 0.560 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 74 | 0.560 |
Why?
|
| Electronic Health Records | 1 | 2017 | 63 | 0.560 |
Why?
|
| Patellofemoral Joint | 3 | 2023 | 66 | 0.550 |
Why?
|
| Algorithms | 6 | 2022 | 363 | 0.540 |
Why?
|
| Osteotomy | 5 | 2017 | 169 | 0.540 |
Why?
|
| Patient Compliance | 1 | 2017 | 145 | 0.530 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2022 | 621 | 0.530 |
Why?
|
| Random Allocation | 6 | 2020 | 119 | 0.530 |
Why?
|
| Hyaluronic Acid | 2 | 2021 | 57 | 0.530 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 252 | 0.510 |
Why?
|
| Orthopedic Surgeons | 1 | 2016 | 27 | 0.510 |
Why?
|
| Decompression, Surgical | 3 | 2012 | 128 | 0.500 |
Why?
|
| Viscosupplementation | 1 | 2015 | 6 | 0.500 |
Why?
|
| Sex Factors | 9 | 2019 | 448 | 0.500 |
Why?
|
| Viscosupplements | 1 | 2015 | 9 | 0.500 |
Why?
|
| Osteolysis | 1 | 2016 | 138 | 0.500 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 305 | 0.490 |
Why?
|
| Patellar Dislocation | 3 | 2023 | 23 | 0.490 |
Why?
|
| Femoral Neck Fractures | 1 | 2015 | 11 | 0.490 |
Why?
|
| Shoulder Prosthesis | 3 | 2020 | 23 | 0.480 |
Why?
|
| Lacerations | 3 | 2013 | 18 | 0.480 |
Why?
|
| Cartilage Diseases | 3 | 2023 | 95 | 0.480 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 51 | 0.470 |
Why?
|
| Incidence | 8 | 2022 | 717 | 0.470 |
Why?
|
| Synovial Membrane | 4 | 2019 | 50 | 0.460 |
Why?
|
| Transplantation, Autologous | 10 | 2019 | 160 | 0.460 |
Why?
|
| Health Care Surveys | 1 | 2014 | 61 | 0.450 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 39 | 0.450 |
Why?
|
| Radiology | 1 | 2013 | 16 | 0.450 |
Why?
|
| Humeral Head | 4 | 2022 | 36 | 0.450 |
Why?
|
| Models, Educational | 1 | 2013 | 33 | 0.440 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 24 | 0.440 |
Why?
|
| Radiography | 11 | 2017 | 614 | 0.440 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 9 | 0.440 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 34 | 0.440 |
Why?
|
| Blood Transfusion | 5 | 2019 | 65 | 0.430 |
Why?
|
| Thromboembolism | 1 | 2013 | 16 | 0.430 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2013 | 4 | 0.430 |
Why?
|
| Hamstring Muscles | 3 | 2018 | 16 | 0.420 |
Why?
|
| Leg Injuries | 1 | 2012 | 7 | 0.410 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 855 | 0.410 |
Why?
|
| Treatment Failure | 9 | 2020 | 149 | 0.400 |
Why?
|
| Evidence-Based Medicine | 5 | 2014 | 186 | 0.400 |
Why?
|
| Case-Control Studies | 8 | 2019 | 564 | 0.400 |
Why?
|
| Arm Injuries | 1 | 2012 | 9 | 0.400 |
Why?
|
| Bone Marrow | 2 | 2023 | 80 | 0.390 |
Why?
|
| Odds Ratio | 4 | 2020 | 265 | 0.390 |
Why?
|
| Hand Injuries | 2 | 2009 | 13 | 0.390 |
Why?
|
| Osseointegration | 1 | 2012 | 69 | 0.380 |
Why?
|
| Child | 17 | 2022 | 1234 | 0.380 |
Why?
|
| Leishmania donovani | 5 | 2013 | 5 | 0.370 |
Why?
|
| Diagnostic Imaging | 4 | 2016 | 72 | 0.370 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 230 | 0.360 |
Why?
|
| Work Capacity Evaluation | 1 | 2010 | 7 | 0.360 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 186 | 0.350 |
Why?
|
| Tensile Strength | 4 | 2019 | 27 | 0.350 |
Why?
|
| Patient Discharge | 5 | 2022 | 147 | 0.350 |
Why?
|
| Prosthesis Failure | 5 | 2014 | 506 | 0.350 |
Why?
|
| Supervised Machine Learning | 2 | 2020 | 15 | 0.350 |
Why?
|
| Area Under Curve | 2 | 2020 | 57 | 0.340 |
Why?
|
| Pectoralis Muscles | 3 | 2015 | 17 | 0.330 |
Why?
|
| Matched-Pair Analysis | 2 | 2020 | 25 | 0.330 |
Why?
|
| Meniscus | 2 | 2020 | 22 | 0.330 |
Why?
|
| Animals | 16 | 2022 | 3396 | 0.330 |
Why?
|
| Psychometrics | 2 | 2021 | 227 | 0.330 |
Why?
|
| Nerve Compression Syndromes | 2 | 2009 | 19 | 0.330 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 47 | 0.320 |
Why?
|
| Arthralgia | 6 | 2016 | 115 | 0.320 |
Why?
|
| Information Systems | 4 | 2021 | 26 | 0.320 |
Why?
|
| Equipment Design | 4 | 2020 | 144 | 0.320 |
Why?
|
| Rotator Cuff Tear Arthropathy | 2 | 2019 | 14 | 0.320 |
Why?
|
| Bibliometrics | 2 | 2022 | 30 | 0.310 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 676 | 0.310 |
Why?
|
| Current Procedural Terminology | 2 | 2020 | 14 | 0.300 |
Why?
|
| Physical Examination | 4 | 2017 | 115 | 0.300 |
Why?
|
| Coracoid Process | 2 | 2018 | 7 | 0.300 |
Why?
|
| Transplantation | 1 | 2008 | 4 | 0.300 |
Why?
|
| Autografts | 4 | 2023 | 31 | 0.300 |
Why?
|
| Synovectomy | 1 | 2007 | 5 | 0.300 |
Why?
|
| Hemiarthroplasty | 4 | 2016 | 35 | 0.300 |
Why?
|
| Prosthesis Design | 3 | 2019 | 482 | 0.290 |
Why?
|
| Hemarthrosis | 1 | 2007 | 20 | 0.290 |
Why?
|
| Humeral Fractures | 2 | 2017 | 21 | 0.290 |
Why?
|
| Injections, Intra-Articular | 5 | 2023 | 89 | 0.290 |
Why?
|
| Lower Extremity | 2 | 2018 | 38 | 0.290 |
Why?
|
| Hemophilia A | 1 | 2007 | 44 | 0.280 |
Why?
|
| India | 6 | 2021 | 19 | 0.280 |
Why?
|
| Eye Injuries | 2 | 1997 | 2 | 0.280 |
Why?
|
| Propionibacterium acnes | 2 | 2018 | 8 | 0.270 |
Why?
|
| Postoperative Care | 6 | 2020 | 132 | 0.270 |
Why?
|
| Patella | 3 | 2023 | 70 | 0.270 |
Why?
|
| Physical Therapy Modalities | 4 | 2018 | 71 | 0.260 |
Why?
|
| Machine Learning | 3 | 2021 | 63 | 0.260 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 935 | 0.260 |
Why?
|
| Chronic Disease | 3 | 2021 | 419 | 0.250 |
Why?
|
| Tissue Banks | 2 | 2018 | 6 | 0.250 |
Why?
|
| Pulmonary Embolism | 2 | 2018 | 61 | 0.250 |
Why?
|
| Reference Values | 4 | 2019 | 184 | 0.250 |
Why?
|
| Meta-Analysis as Topic | 5 | 2015 | 41 | 0.240 |
Why?
|
| Regression Analysis | 4 | 2014 | 253 | 0.240 |
Why?
|
| Debridement | 4 | 2018 | 97 | 0.240 |
Why?
|
| Preoperative Care | 3 | 2020 | 122 | 0.230 |
Why?
|
| Inpatients | 3 | 2022 | 135 | 0.230 |
Why?
|
| Time-to-Treatment | 2 | 2015 | 33 | 0.230 |
Why?
|
| Double-Blind Method | 2 | 2023 | 399 | 0.230 |
Why?
|
| Thigh | 3 | 2018 | 32 | 0.230 |
Why?
|
| Age Distribution | 5 | 2016 | 81 | 0.220 |
Why?
|
| Radiostereometric Analysis | 1 | 2023 | 8 | 0.220 |
Why?
|
| Posterior Cruciate Ligament | 2 | 2020 | 24 | 0.220 |
Why?
|
| Medial Collateral Ligament, Knee | 1 | 2023 | 7 | 0.210 |
Why?
|
| Muscle Weakness | 1 | 2023 | 28 | 0.210 |
Why?
|
| Fascia Lata | 1 | 2023 | 12 | 0.210 |
Why?
|
| Access to Information | 1 | 2022 | 6 | 0.210 |
Why?
|
| Benzophenones | 2 | 2019 | 28 | 0.210 |
Why?
|
| Infectious Mononucleosis | 1 | 2002 | 1 | 0.210 |
Why?
|
| Ketones | 2 | 2019 | 24 | 0.210 |
Why?
|
| Shoulder Impingement Syndrome | 2 | 2014 | 15 | 0.210 |
Why?
|
| Nephritis, Interstitial | 1 | 2002 | 7 | 0.210 |
Why?
|
| Preoperative Period | 2 | 2020 | 78 | 0.210 |
Why?
|
| Early Ambulation | 2 | 2020 | 17 | 0.210 |
Why?
|
| Polymers | 2 | 2019 | 43 | 0.210 |
Why?
|
| Tenotomy | 2 | 2021 | 17 | 0.210 |
Why?
|
| Ilium | 2 | 2014 | 29 | 0.200 |
Why?
|
| Polyethylene Glycols | 2 | 2019 | 44 | 0.200 |
Why?
|
| Clinical Protocols | 2 | 2020 | 55 | 0.200 |
Why?
|
| Video Recording | 2 | 2020 | 33 | 0.200 |
Why?
|
| Ossification, Heterotopic | 1 | 2022 | 36 | 0.200 |
Why?
|
| Recruitment, Neurophysiological | 1 | 2021 | 2 | 0.200 |
Why?
|
| Neurological Rehabilitation | 1 | 2021 | 5 | 0.200 |
Why?
|
| Equipment Failure | 3 | 2017 | 37 | 0.200 |
Why?
|
| Skin | 2 | 2019 | 103 | 0.200 |
Why?
|
| Quadriplegia | 1 | 2021 | 8 | 0.200 |
Why?
|
| Auditory Threshold | 1 | 2021 | 14 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2021 | 313 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 36 | 0.190 |
Why?
|
| Hand | 1 | 2021 | 36 | 0.190 |
Why?
|
| Bone Plates | 1 | 2021 | 51 | 0.190 |
Why?
|
| Pressure | 6 | 2015 | 55 | 0.190 |
Why?
|
| Medicine | 1 | 2001 | 11 | 0.190 |
Why?
|
| Community-Institutional Relations | 1 | 2001 | 14 | 0.190 |
Why?
|
| Cartilage | 3 | 2016 | 104 | 0.190 |
Why?
|
| Specialization | 1 | 2001 | 15 | 0.190 |
Why?
|
| Registries | 2 | 2019 | 177 | 0.190 |
Why?
|
| Spinal Cord Injuries | 1 | 2021 | 38 | 0.190 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 39 | 0.190 |
Why?
|
| Joint Prosthesis | 2 | 2013 | 82 | 0.180 |
Why?
|
| Joint Diseases | 2 | 2020 | 108 | 0.180 |
Why?
|
| Bone Density | 2 | 2019 | 142 | 0.180 |
Why?
|
| Ankle | 1 | 2020 | 21 | 0.180 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 41 | 0.180 |
Why?
|
| Child, Preschool | 6 | 2018 | 592 | 0.180 |
Why?
|
| Perioperative Period | 1 | 2020 | 9 | 0.180 |
Why?
|
| Forecasting | 2 | 2019 | 90 | 0.180 |
Why?
|
| Posterior Cruciate Ligament Reconstruction | 1 | 2020 | 8 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2001 | 99 | 0.180 |
Why?
|
| Analgesia | 1 | 2021 | 35 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 37 | 0.170 |
Why?
|
| Resistance Training | 1 | 2020 | 7 | 0.170 |
Why?
|
| Efficiency | 1 | 2020 | 15 | 0.170 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2020 | 33 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 18 | 0.170 |
Why?
|
| Ultrasonography | 4 | 2009 | 222 | 0.170 |
Why?
|
| Restraint, Physical | 1 | 2020 | 14 | 0.170 |
Why?
|
| Information Dissemination | 1 | 2020 | 17 | 0.170 |
Why?
|
| Body Height | 4 | 2015 | 33 | 0.170 |
Why?
|
| Muscle Fatigue | 2 | 2017 | 9 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 44 | 0.170 |
Why?
|
| Research Subjects | 1 | 2019 | 11 | 0.170 |
Why?
|
| Logistic Models | 1 | 2020 | 365 | 0.170 |
Why?
|
| Transplants | 2 | 2016 | 10 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2019 | 49 | 0.160 |
Why?
|
| Models, Biological | 3 | 2013 | 303 | 0.160 |
Why?
|
| Time | 1 | 2019 | 12 | 0.160 |
Why?
|
| Venous Thrombosis | 2 | 2013 | 44 | 0.160 |
Why?
|
| Bacteria | 1 | 2019 | 74 | 0.160 |
Why?
|
| Patient Positioning | 2 | 2018 | 40 | 0.160 |
Why?
|
| Osteosarcoma, Juxtacortical | 1 | 1999 | 1 | 0.160 |
Why?
|
| Corneal Opacity | 1 | 1999 | 2 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 141 | 0.160 |
Why?
|
| Femoral Neoplasms | 1 | 1999 | 4 | 0.160 |
Why?
|
| Keratoplasty, Penetrating | 1 | 1999 | 9 | 0.160 |
Why?
|
| Propensity Score | 1 | 2019 | 32 | 0.160 |
Why?
|
| Orbital Neoplasms | 1 | 1999 | 7 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 338 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 38 | 0.160 |
Why?
|
| Dyspnea | 1 | 2019 | 39 | 0.160 |
Why?
|
| Mental Health | 1 | 2020 | 105 | 0.160 |
Why?
|
| Rabbits | 3 | 2015 | 180 | 0.160 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2012 | 16 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 140 | 0.160 |
Why?
|
| Motivation | 1 | 2019 | 92 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 50 | 0.160 |
Why?
|
| Intra-Articular Fractures | 1 | 2018 | 21 | 0.160 |
Why?
|
| Weight-Bearing | 5 | 2016 | 163 | 0.150 |
Why?
|
| Doxycycline | 1 | 2018 | 15 | 0.150 |
Why?
|
| Pudendal Nerve | 1 | 2018 | 4 | 0.150 |
Why?
|
| Soccer | 1 | 2018 | 16 | 0.150 |
Why?
|
| Joint Capsule Release | 1 | 2018 | 9 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2017 | 629 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2018 | 12 | 0.150 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2012 | 3 | 0.150 |
Why?
|
| Bursitis | 1 | 2018 | 13 | 0.150 |
Why?
|
| Models, Animal | 3 | 2015 | 106 | 0.150 |
Why?
|
| Anemia | 1 | 2019 | 93 | 0.150 |
Why?
|
| Michigan | 1 | 2017 | 16 | 0.150 |
Why?
|
| Sepsis | 1 | 2019 | 138 | 0.150 |
Why?
|
| Patient Selection | 3 | 2021 | 194 | 0.150 |
Why?
|
| Reimbursement, Incentive | 1 | 2017 | 6 | 0.150 |
Why?
|
| Pneumonia | 1 | 2018 | 70 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 35 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2017 | 16 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 109 | 0.140 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 485 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2018 | 79 | 0.140 |
Why?
|
| Interinstitutional Relations | 1 | 2017 | 9 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2018 | 110 | 0.140 |
Why?
|
| Patient Preference | 1 | 2017 | 30 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 23 | 0.140 |
Why?
|
| Muscular Atrophy | 1 | 2016 | 7 | 0.140 |
Why?
|
| Heart Failure | 1 | 2019 | 171 | 0.140 |
Why?
|
| Hyaline Cartilage | 2 | 2013 | 15 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 459 | 0.140 |
Why?
|
| Comorbidity | 4 | 2019 | 475 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 20 | 0.130 |
Why?
|
| Anterior Chamber | 1 | 1996 | 1 | 0.130 |
Why?
|
| Hyphema | 1 | 1996 | 1 | 0.130 |
Why?
|
| Trabeculectomy | 1 | 1996 | 1 | 0.130 |
Why?
|
| Cornea | 1 | 1996 | 9 | 0.130 |
Why?
|
| Knee | 3 | 2023 | 44 | 0.130 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2013 | 17 | 0.130 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1996 | 7 | 0.130 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2013 | 10 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 48 | 0.130 |
Why?
|
| Deltoid Muscle | 1 | 2015 | 6 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 90 | 0.130 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 185 | 0.130 |
Why?
|
| Synovial Fluid | 2 | 2015 | 93 | 0.130 |
Why?
|
| Liver Abscess, Amebic | 1 | 1995 | 1 | 0.130 |
Why?
|
| Capsaicin | 1 | 2015 | 8 | 0.130 |
Why?
|
| Developing Countries | 1 | 1995 | 12 | 0.130 |
Why?
|
| Biomarkers | 2 | 2015 | 556 | 0.130 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 13 | 0.130 |
Why?
|
| Chondrogenesis | 1 | 2015 | 27 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 29 | 0.120 |
Why?
|
| Chemokines | 1 | 2015 | 21 | 0.120 |
Why?
|
| Visual Analog Scale | 3 | 2020 | 73 | 0.120 |
Why?
|
| Bone-Patellar Tendon-Bone Grafts | 1 | 2014 | 4 | 0.120 |
Why?
|
| Thorax | 1 | 2014 | 11 | 0.120 |
Why?
|
| Torque | 2 | 2017 | 26 | 0.120 |
Why?
|
| Dysgammaglobulinemia | 1 | 2014 | 1 | 0.120 |
Why?
|
| Tissue Donors | 2 | 2009 | 72 | 0.120 |
Why?
|
| Athletic Performance | 1 | 2014 | 21 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 9 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 29 | 0.110 |
Why?
|
| Learning Curve | 1 | 2013 | 15 | 0.110 |
Why?
|
| Rural Population | 2 | 2006 | 23 | 0.110 |
Why?
|
| Publishing | 1 | 2014 | 36 | 0.110 |
Why?
|
| Swine | 4 | 2009 | 65 | 0.110 |
Why?
|
| CD58 Antigens | 1 | 2013 | 1 | 0.110 |
Why?
|
| Knee Prosthesis | 1 | 2016 | 222 | 0.110 |
Why?
|
| Numbers Needed To Treat | 1 | 2013 | 1 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 215 | 0.110 |
Why?
|
| Hip | 1 | 2013 | 48 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 39 | 0.110 |
Why?
|
| Visual Acuity | 3 | 1999 | 37 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2013 | 21 | 0.110 |
Why?
|
| Trypanocidal Agents | 1 | 2012 | 1 | 0.110 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 4 | 0.110 |
Why?
|
| Spleen | 1 | 2012 | 31 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2012 | 23 | 0.100 |
Why?
|
| Infant | 4 | 2018 | 520 | 0.100 |
Why?
|
| Braces | 2 | 2016 | 23 | 0.100 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 31 | 0.100 |
Why?
|
| Sterilization | 1 | 2012 | 9 | 0.100 |
Why?
|
| Arthrography | 2 | 2015 | 28 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 33 | 0.100 |
Why?
|
| Tissue Preservation | 1 | 2012 | 4 | 0.100 |
Why?
|
| Gamma Rays | 1 | 2012 | 16 | 0.100 |
Why?
|
| Elasticity | 2 | 2009 | 30 | 0.100 |
Why?
|
| Ankle Joint | 1 | 2012 | 43 | 0.100 |
Why?
|
| Graft Survival | 1 | 2012 | 90 | 0.100 |
Why?
|
| Endemic Diseases | 3 | 2006 | 7 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2020 | 428 | 0.090 |
Why?
|
| Survivorship | 2 | 2021 | 21 | 0.090 |
Why?
|
| Skilled Nursing Facilities | 2 | 2021 | 23 | 0.090 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 157 | 0.090 |
Why?
|
| Reference Standards | 1 | 2010 | 23 | 0.090 |
Why?
|
| Occupations | 1 | 2010 | 15 | 0.090 |
Why?
|
| Functional Laterality | 1 | 2010 | 62 | 0.090 |
Why?
|
| Cushing Syndrome | 1 | 2010 | 1 | 0.090 |
Why?
|
| Medical Errors | 1 | 2009 | 25 | 0.080 |
Why?
|
| Freezing | 1 | 2009 | 12 | 0.080 |
Why?
|
| Outpatients | 2 | 2021 | 53 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 75 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 63 | 0.080 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2009 | 18 | 0.080 |
Why?
|
| Medicare | 2 | 2021 | 114 | 0.080 |
Why?
|
| Papua New Guinea | 2 | 1999 | 2 | 0.080 |
Why?
|
| Prognosis | 3 | 2019 | 758 | 0.080 |
Why?
|
| Antiprotozoal Agents | 2 | 2013 | 8 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2021 | 207 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 125 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 309 | 0.070 |
Why?
|
| Smoking | 2 | 2019 | 170 | 0.070 |
Why?
|
| Prevalence | 3 | 2015 | 435 | 0.070 |
Why?
|
| Hindlimb | 1 | 2006 | 15 | 0.070 |
Why?
|
| Wuchereria bancrofti | 1 | 2006 | 1 | 0.070 |
Why?
|
| Elephantiasis, Filarial | 1 | 2006 | 2 | 0.070 |
Why?
|
| Hypericum | 1 | 2005 | 3 | 0.060 |
Why?
|
| Traction | 1 | 2005 | 31 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 34 | 0.060 |
Why?
|
| Arthrometry, Articular | 2 | 2017 | 12 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2017 | 60 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2016 | 76 | 0.060 |
Why?
|
| Ligaments | 1 | 2023 | 15 | 0.060 |
Why?
|
| Health Status Indicators | 3 | 2010 | 75 | 0.060 |
Why?
|
| Absorbable Implants | 2 | 2014 | 24 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 25 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 23 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2022 | 1 | 0.050 |
Why?
|
| Posture | 2 | 2015 | 63 | 0.050 |
Why?
|
| Polyethylene | 2 | 2015 | 120 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 26 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2002 | 40 | 0.050 |
Why?
|
| Models, Anatomic | 2 | 2013 | 42 | 0.050 |
Why?
|
| Pentamidine | 1 | 2001 | 2 | 0.050 |
Why?
|
| Northern Territory | 1 | 2001 | 1 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2002 | 108 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 36 | 0.050 |
Why?
|
| Allopurinol | 1 | 2001 | 5 | 0.050 |
Why?
|
| Culture | 1 | 2001 | 24 | 0.050 |
Why?
|
| Femoral Nerve | 1 | 2021 | 9 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 23 | 0.050 |
Why?
|
| Medicaid | 1 | 2021 | 36 | 0.050 |
Why?
|
| Parasitemia | 1 | 2000 | 1 | 0.050 |
Why?
|
| Tracheostomy | 1 | 2020 | 23 | 0.050 |
Why?
|
| Dermis | 1 | 2020 | 7 | 0.050 |
Why?
|
| Psychodidae | 1 | 2000 | 1 | 0.040 |
Why?
|
| DNA Probes | 1 | 2000 | 7 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2001 | 78 | 0.040 |
Why?
|
| Epiphyses | 1 | 2020 | 12 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 17 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 83 | 0.040 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 22 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 127 | 0.040 |
Why?
|
| Quality Control | 1 | 2020 | 27 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2019 | 17 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 38 | 0.040 |
Why?
|
| Morphine | 1 | 2020 | 62 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Hematocrit | 1 | 2019 | 13 | 0.040 |
Why?
|
| Episode of Care | 1 | 2019 | 6 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 21 | 0.040 |
Why?
|
| Eyelid Neoplasms | 1 | 1999 | 3 | 0.040 |
Why?
|
| Conjunctival Neoplasms | 1 | 1999 | 2 | 0.040 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1999 | 2 | 0.040 |
Why?
|
| Pupil | 1 | 1999 | 3 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 22 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 49 | 0.040 |
Why?
|
| Software | 1 | 2019 | 64 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 69 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 239 | 0.040 |
Why?
|
| Dissection | 1 | 2018 | 22 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 2018 | 23 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 162 | 0.040 |
Why?
|
| Survival Rate | 1 | 1999 | 322 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 347 | 0.040 |
Why?
|
| Hockey | 1 | 2017 | 1 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 8 | 0.040 |
Why?
|
| Blindness | 1 | 1997 | 12 | 0.040 |
Why?
|
| Torso | 1 | 2017 | 6 | 0.040 |
Why?
|
| Tarsal Bones | 1 | 2016 | 8 | 0.040 |
Why?
|
| Computer-Aided Design | 1 | 2017 | 15 | 0.030 |
Why?
|
| Online Systems | 1 | 2016 | 4 | 0.030 |
Why?
|
| Ocular Hypertension | 1 | 1996 | 1 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 1996 | 7 | 0.030 |
Why?
|
| Proprioception | 1 | 2016 | 20 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 16 | 0.030 |
Why?
|
| Blood | 1 | 1996 | 17 | 0.030 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 30 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 43 | 0.030 |
Why?
|
| Surgical Tape | 1 | 2015 | 3 | 0.030 |
Why?
|
| Medical Illustration | 1 | 2015 | 14 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 41 | 0.030 |
Why?
|
| Photography | 1 | 2015 | 15 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2015 | 12 | 0.030 |
Why?
|
| Parasite Load | 1 | 2015 | 1 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2015 | 18 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 24 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 124 | 0.030 |
Why?
|
| Chondrocytes | 1 | 2016 | 148 | 0.030 |
Why?
|
| Chemokine CCL19 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 111 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 85 | 0.030 |
Why?
|
| Fibrocartilage | 1 | 2015 | 8 | 0.030 |
Why?
|
| Occupational Injuries | 1 | 2015 | 9 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2015 | 129 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 37 | 0.030 |
Why?
|
| Denmark | 1 | 2014 | 9 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2016 | 121 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 134 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 58 | 0.030 |
Why?
|
| Liver | 1 | 1995 | 123 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 15 | 0.030 |
Why?
|
| Authorship | 1 | 2014 | 14 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2014 | 12 | 0.030 |
Why?
|
| Rituximab | 1 | 2014 | 50 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 264 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 87 | 0.030 |
Why?
|
| Acellular Dermis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2013 | 5 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 60 | 0.030 |
Why?
|
| Metals | 1 | 2014 | 142 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 8 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2013 | 8 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 236 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 100 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 59 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 97 | 0.030 |
Why?
|
| Gene Expression | 1 | 2013 | 180 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2012 | 10 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 190 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 100 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 32 | 0.030 |
Why?
|
| Observer Variation | 1 | 2012 | 93 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2012 | 54 | 0.020 |
Why?
|
| Gait | 1 | 2016 | 408 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 102 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 294 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 117 | 0.020 |
Why?
|
| Body Weight | 2 | 2009 | 121 | 0.020 |
Why?
|
| Neurocysticercosis | 1 | 2010 | 1 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 253 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 22 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 90 | 0.020 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2009 | 15 | 0.020 |
Why?
|
| Prosthesis Fitting | 1 | 2009 | 21 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 130 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2009 | 4 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 95 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 122 | 0.020 |
Why?
|
| Parents | 1 | 2010 | 104 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 1282 | 0.020 |
Why?
|
| Culex | 1 | 2006 | 3 | 0.020 |
Why?
|
| Microfilariae | 1 | 2006 | 2 | 0.020 |
Why?
|
| Insect Vectors | 1 | 2006 | 3 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2005 | 1 | 0.020 |
Why?
|
| Agglutination Tests | 1 | 2005 | 3 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2005 | 3 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 12 | 0.020 |
Why?
|
| Axillary Vein | 1 | 2005 | 1 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2005 | 14 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2005 | 65 | 0.020 |
Why?
|
| Selection Bias | 1 | 2005 | 7 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2005 | 46 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2006 | 378 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 593 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 687 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 114 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 170 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2000 | 19 | 0.010 |
Why?
|
| Digoxigenin | 1 | 2000 | 1 | 0.010 |
Why?
|
| Brain | 1 | 2010 | 1642 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 2000 | 8 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 200 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1977 | 126 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1977 | 13 | 0.000 |
Why?
|
| Health Surveys | 1 | 1977 | 84 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1977 | 99 | 0.000 |
Why?
|
| Attitude to Health | 1 | 1977 | 92 | 0.000 |
Why?
|
| Mass Screening | 1 | 1977 | 166 | 0.000 |
Why?
|